Quality Of Life In Colorectal Cancer Survivors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitute of Oncology Ljubljana
About this trial
The purpose of this study is to identify late adverse effects in colorectal cancer patients that may influence quality of life at 6, 12, and 24 months after oncological treatment. The study aims to assess quality of life in colorectal cancer survivors in relation to psycho-physical-social well-being at different time points and to evaluate the prevalence of late adverse effects and their association with diagnosis and specific oncological treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with colorectal cancer (colon or rectal cancer)
Age 25 to 65 years
First oncological treatment performed at the Institute of Oncology Ljubljana
Working-capable patients
Disqualifiers
Age < 25 years or > 65 years
Patients unable to complete questionnaires
Patients unable to participate in follow-up assessments
Patients who do not provide written informed consent
Trial design
Design model
Single group
Treatments tested in this trial
Quality of Life Assessment
Other interventionQuality of life assessment using questionnaires at 6, 12, and 24 months after oncological treatment.
Treatment groups
368 Participants
are divided into 1 treatment groupGroup A: Quality of Life Assessment GroupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Quality of Life Score (EORTC QLQ-C30 Global Health Status/QoL Scale)
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), specifically the Global Health Status/Quality of Life scale (items 29 and 30). Scores will be linearly transformed to a 0 to 100 scale. Higher scores indicate better quality of life.
Time frame
6, 12, and 24 months after oncological treatmentSecondary outcomes
1
Colorectal Cancer-Specific Quality of Life (EORTC QLQ-CR29)
Colorectal cancer-specific quality of life will be assessed using the EORTC QLQ-CR29 questionnaire. Scores will be linearly transformed to a 0 to 100 scale. Higher scores indicate better functioning for functional scales and worse symptoms for symptom scales.
Time frame
6, 12, and 24 months after oncological treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov